BOOST Pharma Advances Stem Cell Therapy BT-101 for Osteogenesis Imperfecta with Positive Two-Year Data and $4.4M Funding
核心洞察
BOOST Pharma (搜索) presented positive two-year follow-up data from its BOOSTB4 phase 1/2 trial of BT-101, a pioneering stem cell-based therapy for osteogenesis imperfecta (搜索), at the prestigious 15th International Conference on Osteogenesis Imperfecta in Hong Kong.
The company secured SEK 34 million ($3.4 million) in funding through a tranched convertible loan from Sound Bioventures (搜索) to support continued clinical development of BT-101 for the rare bone disease.
Karolinska Development (搜索) exercised its pro rata participation of SEK 7.5 million in BOOST Pharma (搜索)'s financing round, demonstrating continued investor confidence in the stem cell therapy platform.
BOOST Pharma (搜索) has achieved significant milestones in advancing its stem cell-based therapy BT-101 for osteogenesis imperfecta (搜索) (OI), presenting positive two-year follow-up data and securing substantial funding to support phase 3 clinical development preparation.
Positive Long-Term Clinical Data Presented
The company presented new positive long-term data from the BOOSTB4 phase 1/2 trial with BT-101 targeting the rare bone disease osteogenesis imperfecta (搜索). The new results comprise two-year follow-up data from the trial and were selected for presentation at the prestigious 15th International Conference on Osteogenesis Imperfecta in Hong Kong in October 2025.
BT-101 represents a pioneering stem cell-based therapy approach for treating osteogenesis imperfecta (搜索), also known as brittle bone disease (搜索). The sustained positive results over a two-year period demonstrate the potential durability of the therapeutic effect, a critical factor for treating this chronic rare disease.
Substantial Funding Secured for Development
BOOST Pharma (搜索) raised SEK 34 million in November 2025 through an investment structured as a tranched convertible loan from Sound Bioventures (搜索). This funding supports the continued clinical development of BT-101 as the company prepares for phase 3 clinical trials.
Additionally, Karolinska Development (搜索) exercised its pro rata participation of SEK 7.5 million in BOOST Pharma (搜索)'s latest financing round in October 2025. In total, BOOST Pharma's financing, structured as a convertible loan, brought SEK 15 million to the company during this funding round.
Strategic Development Timeline
The investment supports the continued preparation for phase 3 clinical development of BT-101. The combination of positive long-term clinical data and substantial financial backing positions BOOST Pharma (搜索) to advance this pioneering stem cell therapy through the next critical phase of development.
The successful completion of the two-year follow-up analysis and the selection of these results for presentation at the international OI conference underscore the clinical significance of BT-101's therapeutic potential in addressing this rare bone disease that affects patients throughout their lives.